# US 10,502,737 B2 · Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,502,737 B2
- Document ID: US10502737B2
- Status: Granted
- Kind: B2
- Application number: 14/403,337
- Filed: 2013-05-23
- Published: 2015-06-11
- Granted: 2019-12-10
- Earliest claimed: 2012-05-25
- Assignees: The University of Vermont and State Agriculture College
- Applicants: The University of Vermont And State Agriculture College
- Inventors: David Schneider
- Web page: https://patentgrep.com/patent/US10502737B2

## CPC

- G01N 33/56966: {Animal cells}
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- G01N 33/6854: {Immunoglobulins}
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 2333/70535: Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- G01N 2800/222: Platelet disorders
- G01N 2800/226: Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and methods are provided for determining platelet reactivity where the levels of FcγRIIa on the surface of platelets is measured and if the levels of FcγRIIa are greater than a reference value, the platelets have enhanced reactivity.

## Claims

### Claim 1

A method of treating a selected subject at risk of thrombosis with an anti-thrombotic therapy, the method comprising:
administering an anti-thrombotic agent that is an Adenosine diphosphate (ADP) receptor antagonist and/or a Protease-activated receptor (PAR) antagonist to the selected subject, wherein the subject is selected by
determining a level of FcγRIIa expressed on platelets from the subject, wherein a level greater than about 7,500 copies of FcγRIIa per platelet identifies the subject at risk of thrombosis and in need for anti-thrombotic therapy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Adenosine diphosphate (ADP) receptor antagonist and/or the Protease-activated receptor (PAR) antagonist is one or more of prasugrel, ticagrelor, clopidogrel, and vorapaxar.

### Claim 3 (depends on 1)

The method of claim 1, wherein the level of the FcγRIIa is determined by detecting binding between an FcγRIIa-binding conjugate and FcγRIIa.

### Claim 4 (depends on 3)

The method of claim 3, wherein the FcγRIIa-binding conjugate is an anti-FcγRIIa antibody.

### Claim 5 (depends on 1)

The method of claim 1, wherein the level of platelet FcγRIIa is determined using an assay selected from the group consisting of flow cytometry, immunoassay, ELISA, western blotting, and radioimmunoassay.